Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
Analyses will be presented demonstrating similarities between AXS-05 and the potent and fast-acting antidepressant ketamine, based on mechanisms of action and functional animal data. Data from a Phase 1 pharmacokinetic trial of AXS-05 will also be presented along with analyses showing attainment of drug levels that target CNS receptors relevant to neuropsychiatric disorders. AXS-05 is currently being evaluated in a Phase 3 trial in treatment resistant depression, a Phase 2/3 trial in agitation associated with Alzheimer’s disease, and a Phase 2 trial in smoking cessation.
Below are the details of the presentation, which will be given by Cedric O’Gorman, M.D., Senior Vice President, Clinical Development and Medical Affairs of Axsome:
Title: AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development
Poster Number: T16
AXS-05 combines monoamine, glutamatergic and anti-inflammatory mechanisms of action. The biological pathways targeted by these pharmacological actions have been implicated in depressive disorders and in the neuropsychiatric symptoms of Alzheimer’s disease.
A copy of the poster will be available shortly after the meeting on Axsome’s website at www.axsome.com.
AXS-05 is a novel, oral, investigational medicine under development for the treatment of central nervous system (CNS) disorders. AXS-05 consists of bupropion and dextromethorphan and utilizes Axsome’s metabolic inhibition technology. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, nicotinic acetylcholine receptor antagonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is not approved by the
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for its current product candidates, including statements regarding the timing of initiation, interim analyses and completion of the trials; the timing of and the Company’s ability to obtain and maintain
Source: Axsome Therapeutics, Inc.